The coronavirus pandemic has continued to spread throughout the world with 109 million confirmed cases and 2.4 million deaths as recorded in Feb 2021. There is a growing need for safe vaccines to prevent COVID19 throughout the world. The NVX-CoV2373 vaccine contains Matrix M1 adjuvant and Recombinant SARS-Co-V-2 nanoparticle constructed from full-length wild type SARS-Co-V-2 spike glycoprotein, which serves as the target for the development of antibodies. Targeting SARS-Co-V-2 spike glycoprotein is highly effective as per the research of COVID19 vaccines.
A study was conducted which suggested that the NVX-CoV2373 vaccine was highly immunogenic and well-tolerated based on a phase 1 trial. The 2 dose regime of 5 micrograms of NVX-CoV2373 vaccine, administered 21 days apart, was considered the optimal dose. There were two immunogenicity outcomes which were as follows: the anti-spike protein building IgG and Neutralizing Antibodies (NAb) responses. Following 1 st vaccination, NVX-CoV2373 vaccine dose levels were well tolerated with no difference in the anti-spike protein building IgG and Neutralizing Antibodies (NAb) responses were noted. Following the 2nd vaccination, both doses of NVX-CoV2373 vaccine remain well tolerated however NVX-CoV2373 vaccine induced robust levels of anti-spike protein building IgG and Neutralizing Antibodies (NAb) responses in both younger and older adults.
There was a high correlation between anti-spike protein building IgG and Neutralizing Antibodies (NAb) suggesting anti-spike immunity indicating neutralization. Based on antibody responses, the low dose, and two immunization regime of 5 micrograms of NVX-CoV2373 vaccine was selected to move into later phase development.
To know more about origin, virology of COVID-19, Click here
To know more about emerging themes in COVID-19, Click here
To know more about how WhiteCoats can help you in your professional advancement, visit www.whitecoats.com
Want to set up an online consultation for your practice, Click here